首个高选择性补体5a受体抑制剂——阿伐可泮  

A First-in-class highly selective complement 5a receptor antagonist-avacopan

作　　者：张闪闪 赵紫楠[1] 徐文峰[1] 赵飞 张天齐 金鹏飞[1] ZHANG Shanshan;ZHAO Zinan;XU Wenfeng;ZHAO Fei;ZHANG Tianqi;JIN Pengfei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部,国家老年医学中心、中国医学科学院老年医学研究院、北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《临床药物治疗杂志》2024年第11期31-36,共6页Clinical Medication Journal

摘　　要：阿伐可泮是首个高选择性补体5a受体抑制剂,2024年10月29日在中国获批,用于成人严重、活动性抗中性粒细胞胞浆抗体相关性血管炎(肉芽肿性多血管炎或显微镜下多血管炎)在含糖皮质激素的标准治疗中的辅助治疗,尚不能抵消糖皮质激素的使用。临床研究表明,阿伐可泮的有效性、安全性良好,可以联合现有方案用于抗中性粒细胞胞浆抗体相关性血管炎的治疗。本文对其作用机制、药代动力学、临床评价等信息进行综述,旨在为临床用药提供参考。Avacopan is the first highly selective complement 5a receptor antagonist that was approved in China on October 29,2024,for the adjuvant treatment of severe and active antineutrophil cytoplasmic antibody-associated vasculitis(granulomatous polyangitis or microscopic polyangitis)in adults alongside standard treatment containing glucocorticoids.It cannot replace the use of glucocorticoids.Clinical studies have demonstrated the efficacy and safety of avacopan,supporting its use in combination with existing regimens for the treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis.This article reviews its mechanism of action,pharmacokinetics andclinical evaluation,so as to provide reference for its clinical application.

关 键 词：阿伐可泮 补体5a受体(C5aR)抑制剂 抗中性粒细胞胞浆抗体相关性血管炎 

分 类 号：R977[医药卫生—药品]